TVARDI THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
TVARDI THERAPEUTICS, INC. (TVRD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 275.94 thousand shares for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-11.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2025-03-11
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2024-12-31 was -3.04M shares, a 2886.01% decline year-over-year.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2024-09-30 was 172.14K shares, a 189.53% increase year-over-year.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2024-06-30 was 2.46M shares, a 3684.42% increase year-over-year.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2024-03-31 was 679.16K shares, a 1190.55% increase year-over-year.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 275.94K shares, a 3.53% decline from fiscal 2023.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 286.04K shares, a 19.84% decline from fiscal 2022.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 356.82K shares, a 49.01% increase from fiscal 2021.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2021 was 239.46K shares, a 88.32% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2024-12-31 | -3.04M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -2.86M shares derived: sum of 2 quarters · filed 2025-03-11 | -403.22K shares derived: sum of 3 quarters · filed 2025-03-11 | 275.94K shares 10-K · filed 2025-03-11 |
| 2024-09-30 | 172.14K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 2.63M shares derived: sum of 2 quarters · filed 2024-11-14 | 3.31M shares 10-Q · filed 2024-11-14 | 3.42M shares derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | 2.46M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 3.14M shares 10-Q · filed 2024-08-14 | 3.25M shares derived: sum of 3 quarters · filed 2024-08-14 | 3.31M shares derived: sum of 4 quarters · filed 2024-08-14 |
| 2024-03-31 | 679.16K shares 10-Q · filed 2024-05-13 | 788.12K shares derived: sum of 2 quarters · filed 2024-05-13 | 847.57K shares derived: sum of 3 quarters · filed 2024-05-13 | 912.57K shares derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-12-31 | 108.95K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | 168.41K shares derived: sum of 2 quarters · filed 2024-03-06 | 233.41K shares derived: sum of 3 quarters · filed 2024-03-06 | 286.04K shares 10-K · filed 2024-03-06 |
| 2023-09-30 | 59.46K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 124.46K shares derived: sum of 2 quarters · filed 2023-11-13 | 177.09K shares 10-Q · filed 2023-11-13 | |
| 2023-06-30 | 65.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | 117.63K shares 10-Q · filed 2023-08-07 | ||
| 2023-03-31 | 52.63K shares 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | 356.82K shares 10-K · filed 2023-03-06 | |||
| 2021-12-31 | 239.46K shares 10-K · filed 2022-03-01 | |||
| 2020-12-31 | 127.15K shares 10-K · filed 2021-02-25 | |||
| 2019-12-31 | 322.06K shares 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |